Treatment of Epiretinal Membranes With Ranibizumab (LERM)

Queen's University

Status: Completed

Conditions: Epiretinal Membrane

Treatments: Drug: intravitreal ranibizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT01238393

OPTH-092-10

Details and patient eligibility

About

The purpose of this study is to determine whether intraocular injection of ranibizumab decreases the retinal thickness in patients with epiretinal membranes and reduces associated symptoms.

Enrollment: 11 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• symptomatic idiopathic epiretinal membrane

Exclusion criteria

• vision worse than 6/18 and fit for surgery
• prior vitreoretinal surgery or injection
• diabetes
• any past or current form of retinal vein occlusion or neovascularization
• age-related macular degeneration
• other condition causing significant limitation of visual potential

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

11 participants in 1 patient group

Ranibizumab

Experimental group

Description:

('intravitreal ranibizumab' )

Treatment:

Drug: intravitreal ranibizumab